$1.25
17.92%
Nasdaq, Tue, Feb 04 2025
ISIN
US00534A1025
Symbol
ADGI

Adagio Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Adagio Therapeutics Inc Classifications & Recommendation:

Buy
67%
Hold
33%

Adagio Therapeutics Inc Price Target

Target Price $6.67
Price $1.25
Potential
Number of Estimates 3
3 Analysts have issued a price target Adagio Therapeutics Inc 2026 . The average Adagio Therapeutics Inc target price is $6.67. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 3 analysts: 2 Analysts recommend Adagio Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Adagio Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Adagio Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 25.15

3 Analysts have issued a sales forecast Adagio Therapeutics Inc 2024 . The average Adagio Therapeutics Inc sales estimate is

$25.2m
Unlock
. This is
117.60% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$25.4m 119.72%
Unlock
, the lowest is
$24.7m 113.67%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$176m 599.08%
Unlock
2026
$389m 120.93%
Unlock
2027
$697m 79.46%
Unlock
2028
$834m 19.56%
Unlock

1 Analyst has issued an EBITDA forecast Adagio Therapeutics Inc 2024 . The average Adagio Therapeutics Inc EBITDA estimate is

$-200m
Unlock
. This is
14.17% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-200m 14.17%
Unlock
, the lowest is
$-200m 14.17%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-206m 15.38%
2024
$-200m 2.85%
Unlock
2025
$20.4m 110.21%
Unlock
2026
$-22.9m 212.25%
Unlock
2027
$8.1m 135.37%
Unlock
2028
$49.7m 513.58%
Unlock

EBITDA Margin

2025
11.60% 101.46%
Unlock
2026
-5.89% 150.78%
Unlock
2027
1.16% 119.69%
Unlock
2028
5.96% 413.79%
Unlock

3 Adagio Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Adagio Therapeutics Inc net profit estimate is

$-166m
Unlock
. This is
28.72% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-138m 41.03%
Unlock
, the lowest is
$-196m 15.90%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-216m 18.83%
2024
$-166m 23.21%
Unlock
2025
$13.6m 108.15%
Unlock
2026
$88.5m 553.14%
Unlock
2027
$205m 131.10%
Unlock
2028
$243m 18.71%
Unlock

Net Margin

2025
7.71% 101.17%
Unlock
2026
22.78% 195.46%
Unlock
2027
29.33% 28.75%
Unlock
2028
29.13% 0.68%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.81 -1.39
18.83% 23.20%
P/E negative
EV/Sales 1.76

3 Analysts have issued a Adagio Therapeutics Inc forecast for earnings per share. The average Adagio Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.39
Unlock
. This is
28.72% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.15 41.03%
Unlock
, the lowest is
$-1.64 15.90%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.81 18.83%
2024
$-1.39 23.20%
Unlock
2025
$0.11 107.91%
Unlock
2026
$0.74 572.73%
Unlock
2027
$1.71 131.08%
Unlock
2028
$2.03 18.71%
Unlock

P/E ratio

Current -0.64 78.88%
2024
-0.90 40.63%
Unlock
2025
11.03 1,325.56%
Unlock
2026
1.69 84.68%
Unlock
2027
0.73 56.80%
Unlock
2028
0.62 15.07%
Unlock

Based on analysts' sales estimates for 2024, the Adagio Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.83
2024
1.76 54.04%
Unlock
2025
0.25 85.70%
Unlock
2026
0.11 54.73%
Unlock
2027
0.06 44.30%
Unlock
2028
0.05 16.38%
Unlock

P/S ratio

Current
2024
5.94 54.04%
Unlock
2025
0.85 85.69%
Unlock
2026
0.38 54.73%
Unlock
2027
0.21 44.27%
Unlock
2028
0.18 16.36%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today